Yes, Mounjaro (tirzepatide) is prescription only. The FDA classifies it as an injectable prescription medicine, meaning you cannot legally buy it over the counter at a pharmacy or online without a valid prescription from a licensed healthcare provider. This applies to all doses and forms of the medication.
What Mounjaro Is Approved For
Mounjaro is FDA-approved specifically for adults with type 2 diabetes, used alongside diet and exercise to improve blood sugar control. It works by activating two gut hormone receptors that help regulate blood sugar and appetite.
The same active ingredient, tirzepatide, is also sold under a separate brand name (Zepbound) for weight management. That version is approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher when at least one weight-related condition is present, such as high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease. Zepbound is also prescription only.
Mounjaro itself is not FDA-approved for weight loss. This distinction matters because it affects whether your insurance will cover it and which prescription your doctor writes.
Why It Requires a Prescription
Mounjaro carries an FDA black box warning, the most serious type of safety alert the agency issues. In animal studies, tirzepatide caused thyroid tumors at doses similar to what humans receive. Whether this risk translates to people is still unknown, but the drug is completely off-limits for anyone with a personal or family history of a rare thyroid cancer called medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Beyond the thyroid concern, Mounjaro can cause serious complications that need medical monitoring. These include acute kidney injury, gallbladder disease, and diabetic retinopathy. Gastrointestinal side effects like nausea, vomiting, and diarrhea are common, and in rare cases the drug has triggered bowel obstruction, particularly in patients with a history of abdominal surgeries. A case report published in PMC highlighted a patient who developed kidney injury and bowel paralysis after receiving Mounjaro at a walk-in clinic without established follow-up care, underscoring why ongoing medical oversight matters.
These risks are why the dosing schedule starts low and gradually increases over several months. Your prescriber needs to assess how you’re tolerating the medication before moving to a higher dose.
How the Prescribing Process Works
Getting a Mounjaro prescription typically involves a visit with your primary care doctor, an endocrinologist, or in some cases a telehealth provider. For type 2 diabetes, your doctor will evaluate your blood sugar history, current medications, and overall health before deciding if tirzepatide is appropriate.
If you’re seeking it for weight loss, your provider would prescribe Zepbound instead, since Mounjaro’s approved indication is diabetes only. The prescribing criteria for Zepbound require documented BMI measurements and, for patients in the 27 to 29.9 BMI range, at least one weight-related health condition.
Insurance Coverage and Prior Authorization
Most insurance plans require prior authorization before they’ll cover Mounjaro, which means your doctor submits documentation proving you meet specific criteria. A representative policy from Cigna, for example, approves coverage for one year if you are 18 or older, have type 2 diabetes, and have tried at least one oral diabetes medication.
Insurance plans generally will not cover Mounjaro for weight loss, prediabetes, diabetes prevention, metabolic syndrome without type 2 diabetes, or type 1 diabetes. If your claim is denied, your doctor can appeal, but the process can take weeks. Without insurance coverage, Mounjaro’s retail price runs over $1,000 per month, though manufacturer savings programs exist for eligible patients.
Compounded Versions and Legal Gray Areas
During a nationwide shortage of tirzepatide, some compounding pharmacies began making their own versions. These compounded products still require a prescription. Under federal law, a state-licensed pharmacy can compound tirzepatide only for an individual patient based on a valid prescription, and only when the compounder is not regularly producing copies of the commercially available drug.
The regulatory landscape here has tightened. Tirzepatide no longer appears on the FDA’s drug shortage list, which limits the legal basis for large-scale compounding facilities to produce it. The FDA announced it would not take enforcement action against certain compounders for tirzepatide-related violations until March 19, 2025, but beyond that window, compounded versions face stricter scrutiny. If you’ve been using a compounded product, it’s worth confirming with your provider that your source is still operating within legal boundaries.
No Generic Version Available
There is no generic version of Mounjaro, and one is unlikely for over a decade. Eli Lilly holds multiple patents on tirzepatide, with the earliest expiring in January 2036 and others extending as far as December 2041. The drug also has FDA new chemical entity exclusivity through May 2027 and new patient population exclusivity through December 2028. Until these protections expire and a generic manufacturer files for approval, tirzepatide will only be available as the branded products Mounjaro and Zepbound, both requiring a prescription.